In this piece, we discuss the Top 10 Stocks to Invest in for Financial Stability.

Investors face rising challenges as recession risks in the U.S. surge, CNBC reported on March 25, 2026.

According to the report, geopolitical tensions, particularly the ongoing armed conflict in Iran, are weighing heavily on economists, who believe higher oil prices and broader uncertainty are intensifying pressure. Concerns persist despite Federal Reserve Chair Jerome Powell’s comments last week that the U.S. is not facing stagflation.

Reinforcing the case for market instability is Moody’s Analytics, which projects the probability of a recession within the next 12 months at 48.6%, further adding that risks could climb even higher if the Middle East conflict intensifies. At the same time, Goldman Sachs, Wilmington Trust, and EY Parthenon project recession probabilities of 30%, 45%, and 40%, respectively. These projections are worrisome, as they exceed the average annual recession risk of 20%.

Amid these headwinds, the labor market remains contracted. The market, central to economic growth, helped create only 116,000 jobs in 2025. Reflecting worsened market conditions this year, February saw a loss of 92,000 jobs. Although the healthcare sector defies the trend and continues to experience heavy hiring.

The case for recession builds heavily around oil prices, which have shot up 35% or $1.02 per gallon over the past month, according to the gas prices website AAA. The report highlights a historical trend showing that most recessions are preceded by such energy shocks.

A similar narrative is demonstrated by weakened consumer sentiment. According to a survey conducted by NerdWallet this month, 65% of respondents hold expectations for a recession within a year.

Amid these market challenges, investors increasingly seek opportunities that ensure their financial stability. For such needs, we prepared a list of the top 10 stocks to invest in for financial stability.

Methodology

Our list of the best stocks to buy for financial stability relies on investing forums, analyst reports, and advice from money managers. Furthermore, these companies boast a dividend yield of at least 2% and are popular among hedge funds, top analysts, and billionaires. Finally, we ranked these stocks in ascending order by the number of hedge funds holding stakes in each as of Q4 2025.

“Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).”

Note: We collected data for this article on March 25, 2026.

10. BlackRock, Inc. (NYSE:BLK)

BlackRock, Inc. (NYSE:BLK) is one of the best stocks to buy for financial stability.

As of March 24, 2026, approximately 90% of covering analysts remain confident in BlackRock, Inc. (NYSE:BLK), with the $1,300 consensus price target implying over 30% upside.

BlackRock, Inc. (NYSE:BLK)’s stock profile was recently reviewed by analysts at Evercore ISI, who took an early look at February and incorporated Q1 traditional asset manager flows. Accordingly, the firm trimmed its price target on the stock from $1,275 to $1,235 and maintained an “Outperform” rating.

In an older update from February, analysts at UBS also revisited the stock. Analysts signaled confidence in the company’s growth trajectory following a strong fourth-quarter performance, coupled with constructive management commentary at the UBS Financials Conference and strong momentum in Q1 net inflows. Furthermore, they remain optimistic in BlackRock, Inc. (NYSE:BLK)’s ability to achieve low-to-mid-teens earnings growth and expand margins, citing its management fee growth.

Given the company’s strong outlook, the firm says investors may be willing to value BlackRock, Inc. (NYSE:BLK) at a higher P/E multiple, in the low-20x range. Lastly, analysts highlighted the possibility of high-teens upside from the stock’s trading level at that time.

BlackRock, Inc. (NYSE:BLK) provides investment, advisory, and risk management solutions, including single-asset and multi-asset portfolios.

9. Bristol-Myers Squibb Company (NYSE:BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is included in our list of the best stocks to buy for financial stability.

Bristol-Myers Squibb Company (NYSE:BMY) is facing mixed analyst sentiment, with roughly 60% of covering analysts maintaining mixed ratings on the stock. At the same time, the consensus price target of $63 implies 10% upside.

The recent analyst update came from HSBC, in which analysts emphasized the healthcare sector’s greater resilience relative to the broader market amid heightened macro uncertainty tied to rising geopolitical risks. Furthermore, the firm’s analysts noted limited impact from AI disruption on healthcare stocks.

Looking ahead, the firm remains confident in Bristol-Myers Squibb Company’s (NYSE:BMY) outlook as it expects the sector’s resilience to play a crucial role in driving the stock’s outperformance in the coming quarter.

Accordingly, HSBC boosted its price target on the stock from $53 to $60. As of March 17, 2026, the firm maintains a “Hold” rating on Bristol-Myers Squibb Company (NYSE:BMY).

The analyst update follows the company’s positive late-stage trial results for its experimental oral drug mezigdomide in combination with carfilzomib and dexamethasone for relapsed multiple myeloma. According to the press release dated March 9, 2026, mezigdomide achieved a significant improvement in patient survival compared to the standard regimen. Furthermore, it showed no increased risk of disease worsening and was consistent with its established safety profile.

Commenting on the results, analysts at RBC Capital described the data as an incremental positive, with the American Cancer Society projecting roughly 36,000 new U.S. multiple myeloma cases in 2026, which reflects the therapy’s market potential.

Bristol-Myers Squibb Company (NYSE:BMY) engages in the development and marketing of biopharmaceuticals, including small molecules, biologics, and CAR-T therapies. The company’s focus remains on discovering innovative treatments for oncology, hematology, and other specialty disease areas globally.